CareZeloSearch
English
Menu

Medical technology & trends

ResearchTech & trendsManitoba

Using a Single Dose of Dexamethasone at 0.6 Versus 0.15 mg/kg of Body Weight for the Treatment of Croup: A Multicenter Retrospective Chart Review.

A retrospective study of 14,205 pediatric croup cases in four emergency departments found that a lower 0.15 mg/kg dose of dexamethasone was as effective as the standard 0.6 mg/kg dose regarding return visits. However, the lower dose was linked to a higher rate of hospitalizations, suggesting clinicians should carefully consider the risks when selecting dosages.

When treating pediatric croup, be aware that while a lower dexamethasone dose appears effective, it may be associated with a higher risk of hospitalization.

Read the original

Official source: Using a Single Dose of Dexamethasone at 0.6 Versus 0.15 mg/kg of Body Weight for the Treatment of Croup: A Multicenter Retrospective Chart Review. (opens in a new tab) — Manitoba health research (PubMed)

Report a problem

ResearchTech & trendsCanada

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study

Moderna and Merck's personalized mRNA vaccine intismeran cut the risk of melanoma returning by 42 per cent two years after surgery, in a study of more than 1,100 people with high-risk melanoma. Two years on, 82 per cent of vaccinated patients were recurrence-free, versus 70 per cent on Keytruda alone. The companies are discussing approval with regulators; full results were due at a European oncology meeting in Madrid.

A personalized mRNA vaccine, matched to each patient's tumour, is moving toward approval after a large trial showed a clear gain in living without recurrence.

News source: CBC News (opens in a new tab)

RecallTech & trendsCanada

Azurion 7 Systems

Philips has issued a notice regarding Azurion 7 systems that may contain unauthorized solid-state drives. These incorrect components could lead to system failures, including the loss of imaging capabilities, motorized movement issues, or the inability to access and store patient data.

If you use an Azurion 7 system, be aware that unauthorized drives may cause sudden equipment failure or loss of patient data.

Official source: Health Canada recalls and alerts (opens in a new tab)

RecallTech & trendsCanada

i-STAT hs-TnI Cartridge

Abbott has issued a recall for specific lots of i-STAT hs-TnI cartridges due to manufacturing variability. These cartridges may produce falsely elevated cardiac troponin I results because of reduced interference mitigation. There is no evidence of falsely low test results.

Check your i-STAT hs-TnI cartridge lots against the recall list and stop using any affected units immediately.

Official source: Health Canada recalls and alerts (opens in a new tab)

ResearchTech & trendsCanada

Delay From Hypotension Onset to Appropriate Antifungal Therapy Initiation Is the Critical Determinant of Outcome in Candida Septic Shock.

A study involving Manitoba researchers found that the time taken to start appropriate antifungal therapy is the most significant factor for survival in Candida septic shock. Patients treated within two hours of persistent hypotension had an 86% survival rate, with outcomes worsening by 5% for every hour of delay thereafter.

For patients with suspected Candida septic shock, prioritizing the rapid administration of appropriate antifungal therapy within the first two hours of hypotension is critical.

Official source: Manitoba health research (PubMed) (opens in a new tab)